OpenAI Acquires Orchestra Bio to Develop AI Agents for Drug Research
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
OpenAI has acquired Orchestra Bio and will integrate it into its Rosalind life-sciences platform. The companies aim to build AI agents that track clinical trials, flag delays and propose next steps, potentially shortening a US drug-development process that averages 10–15 years. Deal terms were not disclosed.
Continue in the app — vote & join in ➔Source: The Decoder (AI) · via ahirlevel.hu